Germany Pharmaceuticals Market Size, Share & Forecast 2031

Germany Pharmaceuticals Market Size, Share & Forecast 2031

Segments - Germany Pharmaceuticals Market by Drug Classes (Anti-Cancer, Anti-diabetics, Anti-rheumatics, Vaccines, Anti-viral, Immunosuppressants, Bronchodilators, Dermatological, Anti-hypertensive, and Others), Applications (Oncology [Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, and Others], Infectious Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Immunological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Respiratory Diseases, Ophthalmology, Dermatology Disorders, and Others), Types (Branded and Generics), and Formulations (Solid Formulation [Tablets, Capsules, and Others] and Liquid & Semi-Liquid Formulation [Oral, Topical, Sublingual & buccal, Rectal, and Parenteral]) - Germany Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-709 | 4.9 Rating | 78 Reviews | 155 Pages | Format : PDF Excel PPT

Report Description


The Germany Pharmaceuticals market size was valued at USD 49.46 billion in 2022, and is projected to reach USD 82.85 billion by 2031, with a CAGR of 5.9% from 2023 – 2031. The growth of the market is attributed to the rising patent applications which are focused on the determination of the latest drug delivery systems, formulations, and new drugs.

The European Patent Office or the EPO Patent Index of 2019 shows that the number of patent applications has risen by 4.3% in 2018 in this pharmaceutical field. Pharmaceutical organizations discover, produce, develop and market pharmaceutical drugs for usage as medications that can be self-administered to all patients, which can vaccinate them, alleviate their symptoms, and cure them with proper diagnosis and treatment.

Germany Pharmaceuticals Market Outlook

These firms can deal in brand or generic medical devices and medications. They have their own subject to regulations and laws that govern the testing, efficacy, marketing, safety, and patenting of drugs.

The research and development tasks that these firms are operational upon include a wide variety of activities from introductory & basic research to late-stage development involving genetic engineering, assay development, efficacy & safety tests in animal models, clinical trials that involves humans, target validation, and lead optimization plus hit exploration using candidates as a service.

According to the WHO report survey of 2020, the cost of research every pharmaceutical firm undertakes ranges from one billion for every individual project ranging to various activities such as marketing, financing, patenting, and supply chain.

The COVID-19 pandemic made a significant impact on the pharmaceutical market, including Germany, owing to the social distancing and restrictions involving travel disrupting supply chains to transport drugs to other countries or even within Germany.

However, the shift began when the hospital, government authorities, and administration bodies decided to increase their investments and funding to the pharmaceutical firms to focus their activities on the coronavirus vaccine. This benefitted the pharmaceutical industry as they had access to and played a crucial role in the supply chain management of the vaccination. This along with the further investment by the pharmaceutical & biotech firms in artificial intelligence & machine learning becomes a major reason for the boosting of the pharmaceutical market.

  • An increase in spending and investment in research and development activities is the primary reason for the projection for boosting the German pharmaceuticals market growth during the forecast period, 2021-2028.

  • There have been significant changes in the drug approval process by their respective regional administration bodies, making it more lenient and swift. In the United States, the Century Cures bill was passed on the primary notion of increasing the pace of the launch of medical devices and breakthrough drugs. These modifications in the approval processes are major factors boosting the German pharmaceuticals market growth.

  • High prices for the development of drugs, diagnosis, and treatments and high cost & maintenance of services from the company’s perspective are anticipated to hinder the German pharmaceuticals market growth. This becomes extremely difficult to function in developing countries such as India, South Africa, and Brazil where there is limited healthcare infrastructure that the pharmaceutical companies can leverage.

  • Lack of standardization in the biotechnology & pharmaceutical firms does not necessarily comply with international regulatory requirements can lead to quality issues and thereby can present as main challenges that can restrict the market expansion in the coming years.

  • R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have now discovered advanced diagnostic techniques such as customized care that can shorten any product’s life cycle which can thereby lead to the rapid development of the latest drug products and derivatives.

Scope of the Report

The report on the German pharmaceuticals market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pharmaceuticals Market - Germany Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Drug Classes (Anti-Cancer, Anti-diabetics, Anti-rheumatics, Vaccines, Anti-viral, Immunosuppressants, Bronchodilators, Dermatological, Anti-hypertensive, and Others), Applications (Oncology [Breast Cancer, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, and Others], Infectious Diseases, Cardiovascular Diseases, Central Nervous System Disorders, Immunological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Respiratory Diseases, Ophthalmology, Dermatology Disorders, and Others), Types (Branded and Generics), and Formulations (Solid Formulation [Tablets, Capsules, and Others] and Liquid & Semi-Liquid Formulation [Oral, Topical, Sublingual & buccal, Rectal, and Parenteral])

Regional Scope

Germany

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast

Key Players Covered in the Report

Boehringer Ingelheim International GmbH; Bayer AG; Merck & Co Inc; Fresenius Kabi AG; STADA Arzneimittel AG; Pfizer Inc; Abbott Laboratories; Abbvie Inc; Teva Pharmaceuticals Industries Ltd; and Novartis AG

Germany Pharmaceuticals Market Segment Insights

Anti-cancer segment is projected to represent a large market share

Based on drug classes, the Germany pharmaceuticals market is divided into anti-cancer, anti-diabetics, anti-rheumatics, vaccines, anti-viral, immunosuppressants, bronchodilators, dermatological, anti-hypertensive, and others. The anti-cancer segment is expected to constitute a major share of 15.5% of the market during the forecast years, 2021-2028 owing to the increase in merger & acquisition activities with respect to the constant change of regular protocols.

There has also been a significant development on the activities which fall under the anti-cancer segment including the treatment of different viruses that can cause cancer. Recently the studies have been shifting towards the coronavirus , as German scientists were the first ones to patent the paper upon how the coronavirus can severely affect cancer patient. This improved the research activities holding upon the anti-cancer segment.

Oncology segment is anticipated to register a major market share

On the basis of applications, the Germany pharmaceuticals market is segmented into oncology, infectious diseases, cardiovascular diseases, central nervous system disorders, immunological disorders, metabolic disorders, gastrointestinal disorders, respiratory diseases, ophthalmology, dermatology disorders, and others.

The oncology segment is further segmented into breast cancer, lung cancer, colorectal cancer, ovarian cancer, prostate cancer, and others. The oncology segment is expected to constitute a major share of 15.4% of the market during the forecast years, 2021-2028 owing to the increase in strategic initiatives and projects such as partnerships, development, collaboration and strengthening of the portfolio. Organizations have also developed new methods for various problems within the oncology study itself, owing to the increasing prevalence of these diseases.

Germany Pharmaceuticals Market Application

Branded segment is estimated to reach the largest market share

On the basis of types, the Germany pharmaceuticals market is bifurcated into branded and generics. The branded segment is expected to constitute a major share of 15.4% of the market during the forecast years, 2021-2028 owing to the increasing adaption of latest therapies, along with the strategic partnerships which drive the wide-scale penetration of branded drugs.

The introduction of biosimilars has announced a major shift in various cancer treatments in Germany. This was a follow through study from the branded drugs perspective when biosimilars were introduced.

Solid Formulation segment is expected to account for the largest market share

Based on formulations, the Germany pharmaceuticals market is bifurcated into solid formulation and liquid & semi-liquid formulation. The solid formulation segment is further segmented into tablets, capsules, and others. The liquid & semi-liquid formulation segment is further segmented into oral, topical, sublingual & buccal, rectal, and parenteral.

The solid formulation segment is expected to register a significant CAGR during the forecast years, 2021-2028 owing to the several benefits including cost-effectiveness with respect to their cost. The administrative bodies of the pharmaceutical organizations have been focusing upon new strategic initiatives to expand their presence outside Germany, and with the solid formulation.

Segments

The Germany pharmaceuticals market size has been segmented in terms of

Drug Classes

  • Anti-Cancer
  • Anti-diabetics
  • Anti-rheumatics
  • Vaccines
  • Anti-viral
  • Immunosuppressants
  • Bronchodilators
  • Dermatological
  • Anti-hypertensive
  • Others

Applications

  • Oncology
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Others
  • Infectious Diseases
  • Cardiovascular Diseases
  • Central Nervous System Disorders
  • Immunological Disorders
  • Metabolic Disorders
  • Gastrointestinal Disorders
  • Respiratory Diseases
  • Ophthalmology
  • Dermatology Disorders
  • Others

Types

  • Branded
  • Generics

Formulations

  • Solid Formulation
    • Tablets
    • Capsules
    • Others
  • Liquid & Semi-Liquid Formulation
    • Oral
    • Topical
    • Sublingual & buccal
    • Rectal
    • Parenteral

Key Players

  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Merck & Co Inc
  • Fresenius Kabi AG
  • STADA Arzneimittel AG
  • Pfizer Inc
  • Abbott Laboratories
  • Abbvie Inc
  • Teva Pharmaceuticals Industries Ltd
  • Novartis AG

Competitive Landscape

Major players competing in the Germany pharmaceuticals market are Boehringer Ingelheim International GmbH; Bayer AG; Merck & Co Inc; Fresenius Kabi AG; STADA Arzneimittel AG; Pfizer Inc; Abbott Laboratories; Abbvie Inc; Teva Pharmaceuticals Industries Ltd; and Novartis AG.

These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For example, Merck & Co Inc signed a collaboration project with Dohme Corporation for the Ebola and COVID vaccinations for the entire distribution across Germany and have been approved by the European Union.

 Germany Pharmaceuticals Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pharmaceuticals Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pharmaceuticals Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pharmaceuticals Market - Supply Chain
  4.5. Global Pharmaceuticals Market Forecast
     4.5.1. Pharmaceuticals Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pharmaceuticals Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pharmaceuticals Market Absolute $ Opportunity
5. Global Pharmaceuticals Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Pharmaceuticals Market Size and Volume Forecast by Types
     5.3.1. Branded
     5.3.2. Generics
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Pharmaceuticals Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Pharmaceuticals Market Size and Volume Forecast by Applications
     6.3.1. Oncology
     6.3.2. Breast Cancer
     6.3.3. Lung Cancer
     6.3.4. Colorectal Cancer
     6.3.5. Ovarian Cancer
     6.3.6. Prostate Cancer
     6.3.7. Others
     6.3.8. Infectious Diseases
     6.3.9. Cardiovascular Diseases
     6.3.10. Central Nervous System Disorders
     6.3.11. Immunolo
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Pharmaceuticals Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Pharmaceuticals Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Pharmaceuticals Demand Share Forecast, 2019-2026
8. North America Pharmaceuticals Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Pharmaceuticals Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Pharmaceuticals Market Size and Volume Forecast by Types
     8.4.1. Branded
     8.4.2. Generics
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Pharmaceuticals Market Size and Volume Forecast by Applications
     8.7.1. Oncology
     8.7.2. Breast Cancer
     8.7.3. Lung Cancer
     8.7.4. Colorectal Cancer
     8.7.5. Ovarian Cancer
     8.7.6. Prostate Cancer
     8.7.7. Others
     8.7.8. Infectious Diseases
     8.7.9. Cardiovascular Diseases
     8.7.10. Central Nervous System Disorders
     8.7.11. Immunolo
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Pharmaceuticals Demand Share Forecast, 2019-2026
9. Latin America Pharmaceuticals Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Pharmaceuticals Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Pharmaceuticals Market Size and Volume Forecast by Types
     9.4.1. Branded
     9.4.2. Generics
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Pharmaceuticals Market Size and Volume Forecast by Applications
     9.7.1. Oncology
     9.7.2. Breast Cancer
     9.7.3. Lung Cancer
     9.7.4. Colorectal Cancer
     9.7.5. Ovarian Cancer
     9.7.6. Prostate Cancer
     9.7.7. Others
     9.7.8. Infectious Diseases
     9.7.9. Cardiovascular Diseases
     9.7.10. Central Nervous System Disorders
     9.7.11. Immunolo
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Pharmaceuticals Demand Share Forecast, 2019-2026
10. Europe Pharmaceuticals Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Pharmaceuticals Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Pharmaceuticals Market Size and Volume Forecast by Types
     10.4.1. Branded
     10.4.2. Generics
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Pharmaceuticals Market Size and Volume Forecast by Applications
     10.7.1. Oncology
     10.7.2. Breast Cancer
     10.7.3. Lung Cancer
     10.7.4. Colorectal Cancer
     10.7.5. Ovarian Cancer
     10.7.6. Prostate Cancer
     10.7.7. Others
     10.7.8. Infectious Diseases
     10.7.9. Cardiovascular Diseases
     10.7.10. Central Nervous System Disorders
     10.7.11. Immunolo
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Pharmaceuticals Demand Share Forecast, 2019-2026
11. Asia Pacific Pharmaceuticals Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Types
     11.4.1. Branded
     11.4.2. Generics
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Pharmaceuticals Market Size and Volume Forecast by Applications
     11.7.1. Oncology
     11.7.2. Breast Cancer
     11.7.3. Lung Cancer
     11.7.4. Colorectal Cancer
     11.7.5. Ovarian Cancer
     11.7.6. Prostate Cancer
     11.7.7. Others
     11.7.8. Infectious Diseases
     11.7.9. Cardiovascular Diseases
     11.7.10. Central Nervous System Disorders
     11.7.11. Immunolo
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Pharmaceuticals Demand Share Forecast, 2019-2026
12. Middle East & Africa Pharmaceuticals Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Types
     12.4.1. Branded
     12.4.2. Generics
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Pharmaceuticals Market Size and Volume Forecast by Applications
     12.7.1. Oncology
     12.7.2. Breast Cancer
     12.7.3. Lung Cancer
     12.7.4. Colorectal Cancer
     12.7.5. Ovarian Cancer
     12.7.6. Prostate Cancer
     12.7.7. Others
     12.7.8. Infectious Diseases
     12.7.9. Cardiovascular Diseases
     12.7.10. Central Nervous System Disorders
     12.7.11. Immunolo
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Pharmaceuticals Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Pharmaceuticals Market: Market Share Analysis
  13.2. Pharmaceuticals Distributors and Customers
  13.3. Pharmaceuticals Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Boehringer Ingelheim International GmbH
     13.4.2. Bayer AG
     13.4.3. Merck & Co Inc
     13.4.4. Fresenius Kabi AG
     13.4.5. STADA Arzneimittel AG
     13.4.6. Pfizer Inc
     13.4.7. Abbott Laboratories
     13.4.8. Abbvie Inc
     13.4.9. Teva Pharmaceuticals Industries Ltd
     13.4.10. Novartis AG

Methodology

Our Clients

General Electric
Deloitte
Siemens Healthcare
Nestle SA
FedEx Logistics
The John Holland Group
Microsoft
Dassault Aviation